Meta-analysis of 3 phase III trials (1895 patients) in BCG-naïve high-risk NMIBC: adding PD-1/PD-L1 inhibitors to BCG raised grade ≥3 treatment-related adverse events (RR 4.02) and discontinuation (RR 2.87), mainly immune-mediated; local urinary events were largely similar.
Meta-analysisn = 1,895
Ciccarese et al. Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis